Capricor Therapeutics (NASDAQ:CAPR) Receives Buy Rating from HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $77.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 450.28% from the company’s previous close.

Separately, Cantor Fitzgerald raised their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Up 2.4 %

Shares of Capricor Therapeutics stock traded up $0.32 during trading on Tuesday, reaching $13.99. The company’s stock had a trading volume of 2,873,292 shares, compared to its average volume of 1,006,827. The business has a 50 day moving average price of $14.41 and a 200-day moving average price of $13.87. The company has a market capitalization of $636.26 million, a P/E ratio of -13.23 and a beta of 4.08. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40.

Hedge Funds Weigh In On Capricor Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CAPR. Magnus Financial Group LLC purchased a new stake in Capricor Therapeutics during the 4th quarter worth approximately $276,000. State Street Corp increased its stake in shares of Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after buying an additional 111,291 shares during the last quarter. JPMorgan Chase & Co. increased its position in Capricor Therapeutics by 419.5% in the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company’s stock worth $855,000 after buying an additional 45,381 shares during the period. Point72 Asset Management L.P. acquired a new position in Capricor Therapeutics during the 3rd quarter valued at about $3,806,000. Finally, Black Diamond Financial LLC bought a new position in Capricor Therapeutics during the 4th quarter valued at $3,833,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.